CoChat
Sign Up
Cited by 384Schizophrenia research and treatmentDiabetes, Cardiovascular Risks, and LipoproteinsHIV-related health complications and treatments

The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.

Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders: Baseline Results From the RAISE-ETP Study

Correll, Christoph U., Robinson, Delbert G., Schooler, Nina R., Brunette, Mary F., Mueser, Kim T., Rosenheck, Robert A., Marcy, Patricia, Addington, Jean, Estroff, Sue E., Robinson, James, Penn, David L., Azrin, Susan, Goldstein, Amy, Severe, Joanne, Heinssen, Robert, Kane, John M.·2014·JAMA Psychiatry
DOI 10.1001/jamapsychiatry.2014.1314
Open this paper in CoChat — free account

Abstract

IMPORTANCE: The fact that individuals with schizophrenia have high cardiovascular morbidity and mortality is well established. However, risk status and moderators or mediators in the earliest stages of illness are less clear. OBJECTIVE: To assess cardiometabolic risk in first-episode schizophrenia spectrum disorders (FES) and its relationship to illness duration, antipsychotic treatment duration and type, sex, and race/ethnicity. DESIGN, SETTING, AND PARTICIPANTS: Baseline results of the Recovery After an Initial Schizophrenia Episode (RAISE) study, collected between July 22, 2010, and July 5, 2012, from 34 community mental health facilities without major research, teaching, or clinical FES programs. Patients were aged 15 to 40 years, had research-confirmed diagnoses of FES, and had less than 6 months of lifetime antipsychotic treatment. EXPOSURE: Prebaseline antipsychotic treatment was based on the community clinician's and/or patient's decision. MAIN OUTCOMES AND MEASURES: Body composition and fasting lipid, glucose, and insulin parameters. RESULTS: In 394 of 404 patients with cardiometabolic data (mean [SD] age, 23.6 [5.0] years; mean [SD] lifetime antipsychotic treatment, 47.3 [46.1] days), 48.3% were obese or overweight, 50.8% smoked, 56.5% had dyslipidemia, 39.9% had prehypertension, 10.0% had hypertension, and 13.2% had metabolic syndrome. Prediabetes (glucose based, 4.0%; hemoglobin A1c based, 15.4%) and diabetes (glucose based, 3.0%; hemoglobin A1c based, 2.9%) were less frequent. Total psychiatric illness duration correlated significantly with higher body mass index, fat mass, fat percentage, and waist circumference (all P<.01) but not elevated metabolic parameters (except triglycerides to HDL-C ratio [P=.04]). Conversely, antipsychotic treatment duration correlated significantly with higher non-HDL-C, triglycerides, and triglycerides to HDL-C ratio and lower HDL-C and systolic blood pressure (all P≤.01). In multivariable analyses, olanzapine was significantly associated with higher triglycerides, insulin, and insulin resistance, whereas quetiapine fumarate was associated with significantly higher triglycerides to HDL-C ratio (all P≤.02). CONCLUSIONS AND RELEVANCE: In patients with FES, cardiometabolic risk factors and abnormalities are present early in the illness and likely related to the underlying illness, unhealthy lifestyle, and antipsychotic medications, which interact with each other. Prevention of and early interventions for psychiatric illness and treatment with lower-risk agents, routine antipsychotic adverse effect monitoring, and smoking cessation interventions are needed from the earliest illness phases.

Overview

Integrity signals

Registry

Crossref · 10.1001/jamapsychiatry.2014.1314

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 88 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Correll, C. U., Robinson, D. G., Schooler, N. R., Brunette, M. F., Mueser, K. T., Rosenheck, R. A., Marcy, P., Addington, J., Estroff, S. E., Robinson, J., Penn, D. L., Azrin, S., Goldstein, A., Severe, J., Heinssen, R., & Kane, J. M.
Affiliations
  • Northwell Health (US)
  • Geisel School of Medicine at Dartmouth, Dartmouth, New Hampshire7Bureau of Behavioral Health, Department of Health and Human Services, Dartmouth, New Hampshire
  • Boston University (US)
  • Yale University (US)
  • University of Calgary (CA)
  • University of North Carolina at Chapel Hill (US)
  • Nathan Kline Institute for Psychiatric Research (US)
  • National Institute of Mental Health (US)
ORCID
Venue
JAMA Psychiatry
Publisher
American Medical Association (AMA)
Published
2014-12-01
Volume
71
Issue
12
Pages
1350
ISSN
2168-622X (ISSN-L)
DOI
10.1001/jamapsychiatry.2014.1314
OpenAlex
W2134164029
Cited by
384
References
88
Citations by year
2026: 11 · 2025: 18 · 2024: 27 · 2023: 22 · 2022: 33 · 2021: 35 · 2020: 40 · 2019: 31 · 2018: 39 · 2017: 45 · 2016: 39 · 2015: 39 · 2014: 2
FWCI
31.79
Type
journal article
Language
en
Open access
closed
Locations
  • JAMA Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Public Health Service (HHSN271200900019C)
  • National Institute of Mental Health (R03MH112053)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Keywords
cardiometabolic risk, first-episode schizophrenia, schizophrenia spectrum disorders, antipsychotic treatment duration, olanzapine, metabolic syndrome, dyslipidemia, insulin resistance, prediabetes, obesity, smoking, hypertension, body composition, HDL cholesterol
MeSH terms
Adolescent, Adult, Blood Glucose, Body Composition, Cardiovascular Diseases, Ethnicity, Female, Humans, Insulin, Lipids, Male, Middle Aged, Obesity, Prospective Studies, Psychotic Disorders, Risk Factors, Schizophrenia, Sex Factors, Time Factors, Antipsychotic Agents, Metabolic Syndrome, Overweight, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review